Skip navigation
Universidade de Brasília
Use este identificador para citar ou linkar para este item: http://repositorio.unb.br/handle/10482/33729
Arquivos associados a este item:
Arquivo TamanhoFormato 
ARTIGO_ControversialIssuesManagement.pdf489,09 kBAdobe PDFVisualizar/Abrir
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorVilar, Luciopt_BR
dc.contributor.authorAbucham, Juliopt_BR
dc.contributor.authorAlbuquerque, José Lucianopt_BR
dc.contributor.authorAraujo, Luiz Antôniopt_BR
dc.contributor.authorAzevedo, Monalisa F.pt_BR
dc.contributor.authorBoguszewski, Cesar Luizpt_BR
dc.contributor.authorCasulari, Luiz Augustopt_BR
dc.contributor.authorCunha Neto, Malebranche B. C.pt_BR
dc.contributor.authorCzepielewski, Mauro Antoniopt_BR
dc.contributor.authorDuarte, Felipe H. G.pt_BR
dc.contributor.authorFaria, Manuel dos S.pt_BR
dc.contributor.authorGadelha, Monica R.pt_BR
dc.contributor.authorGarmes, Heraldo M.pt_BR
dc.contributor.authorGlezer, Andreapt_BR
dc.contributor.authorGurgel, Maria Helanept_BR
dc.contributor.authorJallad, Raquel S.pt_BR
dc.contributor.authorMartins, Manoelpt_BR
dc.contributor.authorMiranda, Paulo A. C.pt_BR
dc.contributor.authorMontenegro, Renan M.pt_BR
dc.contributor.authorMusolino, Nina R. C.pt_BR
dc.contributor.authorNaves, Luciana Ansanelipt_BR
dc.contributor.authorRibeiro-Oliveira Júnior, Antôniopt_BR
dc.contributor.authorSilva, Cíntia M. S.pt_BR
dc.contributor.authorViecceli, Camilapt_BR
dc.contributor.authorBronstein, Marcello D.pt_BR
dc.date.accessioned2019-01-02T13:57:53Z-
dc.date.available2019-01-02T13:57:53Z-
dc.date.issued2018pt_BR
dc.identifier.citationVILAR, Lucio et al. Controversial issues in the management of hyperprolactinemia and prolactinomas: an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, São Paulo, v. 62, n. 2, p. 236-263, mar. 2018. DOI: http://dx.doi.org/10.20945/2359-3997000000032. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000200236&lng=en&nrm=iso. Acesso em: 29 jan. 2019.pt_BR
dc.identifier.urihttp://repositorio.unb.br/handle/10482/33729-
dc.language.isoenpt_BR
dc.publisherSociedade Brasileira de Endocrinologia e Metabologiapt_BR
dc.rightsAcesso Abertopt_BR
dc.titleControversial issues in the management of hyperprolactinemia and prolactinomas : an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolismpt_BR
dc.typeArtigopt_BR
dc.subject.keywordHiperprolactinemiapt_BR
dc.subject.keywordProlactinomapt_BR
dc.subject.keywordPseudoprolactinomaspt_BR
dc.subject.keywordMacroprolactinapt_BR
dc.subject.keywordDopaminapt_BR
dc.subject.keywordCirurgiapt_BR
dc.subject.keywordTemozolomidapt_BR
dc.rights.licenseArchives of Endocrinology and Metabolism - (CC BY) This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Fonte: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972018000200236&lng=en&nrm=iso. Acesso em: 29 jan. 2019.-
dc.identifier.doihttp://dx.doi.org/10.20945/2359-3997000000032pt_BR
dc.description.abstract1Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they represent an important cause of hypogonadism and infertility in both sexes. The magnitude of prolactin (PRL) elevation can be useful in determining the etiology of hyperprolactinemia. Indeed, PRL levels > 250 ng/mL are highly suggestive of the presence of a prolactinoma. In contrast, most patients with stalk dysfunction, drug-induced hyperprolactinemia or systemic diseases present with PRL levels < 100 ng/mL. However, exceptions to these rules are not rare. On the other hand, among patients with macroprolactinomas (MACs), artificially low PRL levels may result from the so-called “hook effect”. Patients harboring cystic MACs may also present with a mild PRL elevation. The screening for macroprolactin is mostly indicated for asymptomatic patients and those with apparent idiopathic hyperprolactinemia. Dopamine agonists (DAs) are the treatment of choice for prolactinomas, particularly cabergoline, which is more effective and better tolerated than bromocriptine. After 2 years of successful treatment, DA withdrawal should be considered in all cases of microprolactinomas and in selected cases of MACs. In this publication, the goal of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism (SBEM) is to provide a review of the diagnosis and treatment of hyperprolactinemia and prolactinomas, emphasizing controversial issues regarding these topics. This review is based on data published in the literature and the authors' experience.-
dc.description.unidadeFaculdade de Medicina (FMD)-
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro simples do item Visualizar estatísticas



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.